Diversifying Eligibility to Enhance Real-World Results

被引：0
|
作者：
Fayyaz, Fatima [1 ]
Carvajal, Richard D. [1 ]
Devoe, Craig E. [1 ,2 ]
机构：
[1] Northwell Hlth Canc Inst, Lake Suceess, NY USA
[2] Zuckerberg Canc Ctr, 450 Lakeville Rd, Lake Success, NY 11042 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 23期
关键词：
NIVOLUMAB PLUS IPILIMUMAB; MELANOMA PATIENTS; OPEN-LABEL; MULTICENTER; COMBINATION; TRIAL;
D O I：
10.1200/JCO.23.00836
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3895 / +
页数：5
相关论文
共 50 条
  • [1] Balancing real-world problems with real-world results
    Gordon, R
    PHI DELTA KAPPAN, 1998, 79 (05) : 390 - 393
  • [2] Real-world Results
    Kuehn, Bridget M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (17): : 1665 - 1665
  • [3] Real-world results
    Frank, Franziska
    NATURE, 2018, 557 (7703) : 130 - 130
  • [4] Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
    Hakansson, Erik
    Norberg, Helena
    Sjalander, Sara
    Lindmark, Krister
    CARDIOVASCULAR THERAPEUTICS, 2021, 2021
  • [5] Eligibility to COAPT Trial in the Daily Practice: A Real-World Experience
    Zancanaro, Edoardo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (12) : B135 - B136
  • [6] Eligibility to COAPT trial in the daily practice: A real-world experience
    Zancanaro, Edoardo
    Buzzatti, Nicola
    Denti, Paolo
    Guicciardi, Nicolo Azzola
    Melillo, Enrico
    Monaco, Fabrizio
    Agricola, Eustachio
    Ancona, Francesco
    Alfieri, Ottavio
    De Bonis, Michele
    Maisano, Francesco
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2024, 104 (02) : 368 - 377
  • [7] Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population
    Thorvaldsen, Tonje
    Ferrannini, Giulia
    Mellbin, Linda
    Benson, Lina
    Cosentino, Francesco
    Mcmurray, John J., V
    Dahlstrom, Ulf
    Lund, Lars H.
    Savarese, Gianluigi
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (07) : 1050 - 1062
  • [8] Eligibility for acetazolamide in real-world acute heart failure patients
    Gerardo, A.
    Fialho, I.
    Passos, M.
    Miranda, I.
    Mateus, C.
    Beringuilho, M.
    Lopes, J.
    Faria, D.
    Roque, D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 164 - 164
  • [9] Eligibility for vericiguat in a real-world, contemporary heart failure population
    Vergaro, Giuseppe
    Aimo, Alberto
    Gentile, Francesco
    Mandoli, Giulia Elena
    Focardi, Marta
    Castiglione, Vincenzo
    Giannoni, Alberto
    Panichella, Giorgia
    Fornaro, Alessandra
    Carluccio, Erberto
    Liga, Riccardo
    Salatin, Mattia
    Passino, Claudio
    Piepoli, Massimo F.
    Cameli, Matteo
    Cappelli, Francesco
    Di Mario, Carlo
    Emdin, Michele
    ESC HEART FAILURE, 2024, 11 (06): : 3523 - 3529
  • [10] Clinical trial eligibility of a real-world connective tissue disease cohort: Results from the LEAP cohort
    Dyball, Sarah
    Madenidou, Anastasia-Vasiliki
    Rodziewicz, Mia
    Reynolds, John A.
    Herrick, Ariane L.
    Haque, Sahena
    Chinoy, Hector
    Bruce, Ellen
    Parker, Ben
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 67
12345